stockrow
Friday 6 November 2026
Export JSPR’s income statement to Excel — free account
Jasper Therapeutics, Inc.
JSPR Healthcare Biotechnology
- EPS
- +94.3%
- Free cash flow
- +55.7%
Quarter to June 2026, against a year earlier
16.73
16.26
+3,459.57%
Follow JSPR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 6 | 6 | 200 | +477.8% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | 0 | (32) | (31) | (38) | (64) | (71) | (76) | (32) | n/m | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | 0 | 0 | (31) | (38) | (64) | (71) | (76) | (32) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | 0.01 | (51.70) | (26.90) | (10.30) | (6.18) | (4.89) | (3.95) | (1.59) | n/m | ||||||
| Cash flow | — | — | — | (1.47) | 0.00 | (29.56) | (12.57) | (4.99) | (4.29) | (4.03) | (2.10) | +18.3% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | (2.13) | (0.16) | (0.03) | (0.04) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (1.47) | 0.00 | (31.69) | (12.73) | (5.01) | (4.33) | (4.03) | (2.10) | +18.3% | ||||||
| Book value | — | — | — | 20.00 | (57.35) | 61.01 | 9.87 | 7.51 | 4.23 | 0.22 | 0.05 | (53.0%) | ||||||
| Shares, m | — | — | — | 0 | 1 | 1 | 4 | 10 | 15 | 19 | 23 | +106.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | 0 | (34) | (46) | (52) | (63) | (77) | (60) | +143.8% | |||||
| Capex | — | — | — | — | — | (2) | (1) | 0 | (1) | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | 0 | 0 | (36) | (46) | (52) | (63) | (77) | (60) | +143.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | 17 | 80 | 35 | 77 | 61 | 21 | 4 | +57.1% | |||||
| Net debt | — | — | — | (1) | (20) | (85) | (38) | (87) | (72) | (29) | (8) | +69.4% | ||||||
| Shareholders’ equity | — | — | — | 5 | (35) | 70 | 36 | 78 | 62 | 4 | 1 | (3.1%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (50.65) | (52.37) | (53.07) | (90.00) | (81.55) | (131.06) | (109.05) | (131.1) pt | |||||
| ROIC | — | — | — | (2.25) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +2.3 pt | ||||||
| ROE | — | — | — | (0.01) | 210.22 | (178.18) | (71.44) | (112.67) | (101.73) | (230.31) | (255.05) | (230.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 25 | 35 | 45 | 64 | 22 | — | +49.0% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Jasper Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| ALLR Allarity Therapeutics, Inc. | $15.5M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| Median of peers | $15.4M | — | — | −75.61% | — | +14.79% | 62.79% | 0.00% |
Pay and ownership Proxy statement filed 19 October 2026
Ownership
Directors and executive officers, together
3.90%
Velan Capital Management LLC and Affiliates
9.90%
MCN HOLDCO LLC
8.10%
Patrick Crutcher
8.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement